An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)

BACKGROUND: Globally, an estimated 260 million people suffer from depression [1], and there is a clear need for the development of new, alternative antidepressant therapies. In light of problems with the tolerability and efficacy of available treatments [2], a global trend is emerging for patients t...

Descripción completa

Detalles Bibliográficos
Autores principales: Donegan, Carina Joy, Daldegan-Bueno, Dimitri, Sumner, Rachael, Menkes, David, Evans, William, Hoeh, Nicholas, Sundram, Frederick, Reynolds, Lisa, Ponton, Rhys, Cavadino, Alana, Smith, Todd, Roop, Partha, Allen, Nathan, Abeysinghe, Binu, Svirskis, Darren, Forsyth, Anna, Bansal, Mahima, Muthukumaraswamy, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552250/
https://www.ncbi.nlm.nih.gov/pubmed/37798662
http://dx.doi.org/10.1186/s40814-023-01399-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552250/
https://www.ncbi.nlm.nih.gov/pubmed/37798662
http://dx.doi.org/10.1186/s40814-023-01399-8

Ejemplares similares